


Drug and Alcohol Dependence 50 (1998) 257



## Author index

Volume 50 (1998)

Allen. T.J. **50**, 137 Ary, D. **50**, 57 Azrin, R.L. **50**, 39

Badger, G.J. 50, 9, 129
Bateman, D.A. 50, 203
Bauer, L.O. 50, 147
Beardsley, P.M. 50, 123
Bearn, J. 50, 227
Bickel, W.K. 50, 129
Biglan, A. 50, 57
Boardman, C. 50, 1
Bowman, J.A. 50, 177
Bray, J.W. 50, 211
Broers, B. 50, 233
Brooner, R.K. 50, 73

Carnwath, T. 50, 251 Carroll, F.I. 50, 123 Cheeves, C. 50, 187 Chen, K. 50, 109 Cherek, D.R. 50, 137 Chiriboga, C. 50, 203 Cook, C.D. 50, 123 Crowley, T.J. 50, 27

Day H, J. 50, 157 Dolan, K. 50, 197 Dukat, M. 50, 99 Dumont, P. 50, 233 Duncan, S.C. 50, 57 Duncan, T. 50, 167 Duncan, T.E. 50, 57

Fernández-Ruiz, J.J. **50**, 241 Friedlander, H. **50**, 203 Fudala, P.J. **50**, 1 Fuentes, J.A. **50**, 241

Gauthier, C.B. 50, 99 Glass, G.E. 50, 167 Glennon, R.A. **50**, 99 Gordon, L. **50**, 221 Gossop, M. **50**, 227 Grella, B. **50**, 99

Hall, W. 50, 197 Hardman, J.-a. 50, 251 Hasin, D. 50, 19 Heagarty, M.C. 50, 203 Herrick-Davis, K. 50, 99 Higgins, S.T. 50, 9 Hollander, J.R. 50, 73 Huddleston, J. 50, 129

Kandel, D.B. 50, 109 Kaplan, E. 50, 197 Kidorf, M. 50, 73 King, V.L. 50, 73 Kline, J.K. 50, 203 Kosten, T. 50, 221 Kosten, T.R. 50, 187

Latkin, C. **50**, 167 Lennox, R.D. **50**, 211 Lumey, L.H. **50**, 203

Macdonald, M.J. 50, 27 Macfadden, W. 50, 1 Mattick, R.P. 50, 181 M. Carroll, K. 50, 221 McKetin, R. 50, 181 Mehl-Madrona, L. 50, 9 Melton, L. 50, 203 Mikulich, S.K. 50, 27 Mino, A. 50, 233 Moeller, F.G. 50, 137

Nich, C. **50**, 221 Nora Chiang, C. **50**, 1

Page, D. 50, 233

Palumbo, J. 50, 187 Paykin, A. 50, 19 Peters, A.D. 50, 47 Petrakis, I. 50, 221 Petry, N.M. 50, 129 Pinelli, A. 50, 81 Price, L.H. 50, 187

Ramos, J.A. **50**, 241 Reid, M.M. **50**, 47 Rhoades, H.M. **50**, 137 Romero, J. **50**, 241 Rounsaville, B. **50**, 221 Ruiz-Gayo, M. **50**, 241

Sanson-Fisher, R.W. 50, 177 Schmitz, J. 50, 157 Seibyl, J.P. 50, 187 Selby, M.J. 50, 39 Shakeshaft, A.P. 50, 177 Spezia, R. 50, 81 Spiga, R. 50, 157 Steele, P.D. 50, 211 Strang, J. 50, 227

Teitler, M. 50, 99 Tidey, J.W. 50, 9 Trivulzio, S. 50, 81 Tzanis, E. 50, 129

Vela, G. 50, 241

Wasserman, G.A. **50**, 203 Whitmore, E.A. **50**, 27 Wodak, A. **50**, 197 Woods, S.W. **50**, 187


Young, R. 50, 99 Yu, E. 50, 1

Zarkin, G.A. 50, 211





Drug and Alcohol Dependence 50 (1998) 259-261



## Subject index

Volume 50 (1998)

Abstinence; Cerebral: Cocaine: Alcohol: Perfusion defects 50, 187

Abuse liability; Analgesia; Morphine; LY297802; Muscarinic agonist; Subjective drug effects; Humans 50, 129

Acceptability; Computers; Screening; Clinical; Drug and alcohol 50,

Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Geographic information systems; Attrition; Selection bias; Neighborhood characteristics 50, 167

Adolescence; Substance use; Development; Latent growth modeling 50, 57

Adult: Impulsivity; Self-control; Substance dependence; Substance abuse 50, 137

Alcohol; Cerebral; Cocaine; Perfusion defects; Abstinence 50, 187

Alcohol dependence: Alcoholism 50, 19

Alcohol; Dependence; Consequences; Bi-axial; Structural equation modeling 50, 211

Alcoholism: Alcohol dependence 50, 19

Ambulatory detoxification; Opiate withdrawal; Lofexidine; Clonidine 50, 251

Amphetamine; Attention; Memory 50, 181

Analgesia: Morphine; LY297802; Muscarinic agonist; Subjective drug effects; Abuse liability; Humans 50, 129

Attention; Amphetamine; Memory 50, 181

Attrition; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Geographic information systems; Selection bias; Neighborhood characteristics 50, 167

Autoradiography: Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTP; S binding; Cannabinoids; 49-Tetrahydrocannabinol; Opiates: Morphine dependence 50, 241

Bi-axial; Alcohol; Dependence; Consequences; Structural equation modeling 50, 211

Buprenorphine; Naloxone; Opioid-dependence; Treatment 50, 1

Cannabinoid agonist-stimulated [35S]GTPyS binding: Cannabinoid receptor binding: Autoradiography; Cannabinoids; 49-Tetrahydrocannabinol; Opiates; Morphine dependence 50, 241

Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTP;'S binding; Autoradiography; Cannabinoids; 49-Tetrahydrocannabinol; Opiates; Morphine dependence 50, 241

Cannabinoids; Cannabinoid receptor binding; Cannabinoid agoniststimulated [35S]GTP; S binding; Autoradiography; 49-Tetrahydrocannabinol; Opiates; Morphine dependence 50, 241

β-Carbolines; Harmaline; Harmine; Drug discrimination; Hallucinogens; 5-HT<sub>2</sub> receptors; Serotonin 50, 99

Cerebral; Cocaine; Alcohol; Perfusion defects; Abstinence 50, 187

Child development; Cocaine; Intelligence; Prenatal exposure 50, 203

Clinical; Computers; Screening; Acceptability; Drug and alcohol 50, 177

Clonidine; Opiate withdrawal; Lofexidine; Ambulatory detoxification 50, 251

Cocaine; Cerebral: Alcohol; Perfusion defects; Abstinence 50, 187

Cocaine; Dependence; Treatment; Psychopathology; Comorbidity 50, 9

Cocaine: Drug abusers; Neuropsychological; Polysubstance abuse 50, 39

Cocaine; Fluoxetine; Methadone; Opioid; Depression 50, 221

Cocaine: Intelligence: Child development: Prenatal exposure 50, 203

Cocaine: RTI-15: Drug discrimination: Locomotor activity 50, 123

Comorbidity: Cocaine: Dependence: Treatment: Psychopathology 50, 9

Computers; Screening; Acceptability; Clinical; Drug and alcohol 50, 177

Conduct disorder; Marijuana; Drug dependence; Reinforcement (psychology) 50, 27

Consequences; Alcohol; Dependence; Bi-axial; Structural equation modeling 50, 211

0376-8716/98/\$19.00 © 1998 Elsevier Science Ireland Ltd. All rights reserved. PII \$0376-8716(98)00090-8 Contingency management; Employment; Methadone treatment 50,

Control of withdrawal effects; Opioid withdrawal syndrome; Rats; Tizanidine 50, 81

Crime: Methadone treatment outcomes; Scotland; Injecting; HIV risk behaviour 50, 47

Dependence: Alcohol; Consequences; Bi-axial; Structural equation modeling 50, 211

Dependence; Cocaine; Treatment; Psychopathology; Comorbidity 50, 9

Depression: Fluoxetine: Cocaine: Methadone: Opioid 50, 221

Development; Adolescence: Substance use; Latent growth modeling 50, 57

Drug abuse; Heroin; HIV-1; Evoked potentials; EEG; Opiates 50, 147

Drug abusers; Neuropsychological; Polysubstance abuse; Cocaine 50, 39

Drug and alcohol; Computers; Screening; Acceptability; Clinical 50, 177

Drug dependence; Marijuana; Reinforcement (psychology); Conduct disorder 50, 27

**Drug discrimination**:  $\beta$ -Carbolines; Harmaline; Harmine; Hallucinogens; 5-HT, receptors; Serotonin **50**, 99

Drug discrimination: RTI-15: Cocaine: Locomotor activity 50, 123

Drug dosage; Methadone maintenance; Substance abuse; Opioids; Gender 50, 233

EEG; Heroin; HIV-1; Evoked potentials; Drug abuse; Opiates 50, 147

Employment; Methadone treatment; Contingency management 50, 73

Evoked potentials; Heroin; HIV-1; EEG; Drug abuse; Opiates 50, 147

Fluoxetine; Cocaine; Methadone; Opioid; Depression 50, 221

Frequency of marijuana use; Marijuana cessation; Predictors; Reasons for using; Social roles 50, 109

Gender; Methadone maintenance; Substance abuse; Opioids; Drug dosage 50, 233

Geographic information systems; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Attrition; Selection bias; Neighborhood characteristics 50, 167

Hallucinogens: β-Carbolines; Harmaline; Harmine; Drug discrimination; 5-HT<sub>2</sub> receptors; Serotonin **50**, 99

Harmaline;  $\beta$ -Carbolines; Harmine; Drug discrimination; Hallucinogens; 5-HT, receptors; Serotonin **50**, 99

Harmine; β-Carbolines; Harmaline; Drug discrimination; Hallucinogens; 5-HT, receptors; Serotonin 50, 99

Heroin; HIV-1; Evoked potentials; EEG; Drug abuse; Opiates 50, 147

HIV-1; Heroin; Evoked potentials; EEG; Drug abuse; Opiates 50, 147

HIV risk behaviour; Methadone treatment outcomes; Scotland; Injecting; Crime 50, 47

HIV transmission; Prison; Mathematical model; Injecting; Syringe sharing 50, 197

5-HT<sub>2</sub> receptors; β-Carbolines; Harmaline; Harmine; Drug discrimination; Hallucinogens; Serotonin 50, 99

Human immunodeficiency virus; Acquired immunodeficiency syndrome; Injection drug users; Geographic information systems; Attrition; Selection bias; Neighborhood characteristics 50, 167

Humans; Analgesia; Morphine; LY297802; Muscarinic agonist; Subjective drug effects; Abuse liability 50, 129

Humans; Methadone self-administration; Nicotine; Nicotine abstinence 50, 157

Impulsivity; Self-control; Substance dependence; Substance abuse; Adult 50, 137

Injecting; HIV transmission; Prison; Mathematical model; Syringe sharing 50, 197

Injecting; Methadone treatment outcomes; Scotland; Crime; HIV risk behaviour 50, 47

**Injection drug users**; Acquired immunodeficiency syndrome; Human immunodeficiency virus; Geographic information systems; Attrition; Selection bias; Neighborhood characteristics **50**, 167

Intelligence; Cocaine; Child development; Prenatal exposure 50, 203

Latent growth modeling; Adolescence; Substance use; Development 50, 57

Locomotor activity; RTI-15; Cocaine; Drug discrimination 50, 123

Lofexidine; Opiate withdrawal; Clonidine; Ambulatory detoxification 50, 251

Lofexidine; Polydrug abusers; Opiate withdrawal; Methadone 50, 227

LY297802; Analgesia; Morphine; Muscarinic agonist; Subjective drug effects; Abuse liability; Humans 50, 129

Marijuana cessation; Predictors; Reasons for using; Frequency of marijuana use; Social roles 50, 109

Marijuana; Drug dependence; Reinforcement (psychology); Conduct disorder 50, 27

Mathematical model; HIV transmission; Prison; Injecting; Syringe sharing 50, 197

Memory; Amphetamine; Attention 50, 181

Methadone; Fluoxetine; Cocaine; Opioid; Depression 50, 221

Methadone maintenance; Substance abuse; Opioids; Drug dosage; Gender 50, 233

Methadone; Polydrug abusers; Opiate withdrawal; Lofexidine 50, 227

Methadone self-administration; Nicotine; Nicotine abstinence; Humans 50, 157

Methadone treatment; Employment; Contingency management 50, 73

Methadone treatment outcomes; Scotland; Injecting; Crime; HIV risk behaviour 50, 47

Morphine; Analgesia; LY297802; Muscarinic agonist; Subjective drug effects; Abuse liability; Humans 50, 129

Morphine dependence; Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTPγS binding; Autoradiography; Cannabinoids; Δ9-Tetrahydrocannabinol; Opiates 50, 241

Muscarinic agonist; Analgesia; Morphine; LY297802; Subjective drug effects; Abuse liability; Humans 50, 129

Naloxone; Buprenorphine; Opioid-dependence; Treatment 50, 1

Neighborhood characteristics; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Geographic information systems; Attrition; Selection bias 50, 167

Neuropsychological; Drug abusers; Polysubstance abuse; Cocaine 50, 39

Nicotine abstinence; Methadone self-administration; Nicotine; Humans 50, 157

Nicotine; Methadone self-administration; Nicotine abstinence; Humans 50, 157

**Opiates:** Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTP<sub>7</sub>S binding; Autoradiography; Cannabinoids; 49-Tetrahydrocannabinol; Morphine dependence 50, 241

Opiates; Heroin; HIV-1; Evoked potentials; EEG; Drug abuse 50, 147

Opiate withdrawal; Lofexidine; Clonidine; Ambulatory detoxification 50, 251

Opiate withdrawal; Polydrug abusers; Methadone; Lofexidine 50, 227

Opioid-dependence; Buprenorphine; Naloxone; Treatment 50, 1

Opioid; Fluoxetine; Cocaine; Methadone; Depression 50, 221

Opioids; Methadone maintenance; Substance abuse; Drug dosage; Gender 50, 233

Opioid withdrawal syndrome; Rats; Control of withdrawal effects; Tizanidine 50, 81

Perfusion defects; Cerebral; Cocaine; Alcohol; Abstinence 50, 187

Polydrug abusers: Opiate withdrawal; Methadone; Lofexidine 50, 227

Polysubstance abuse; Drug abusers; Neuropsychological; Cocaine 50, 39

Predictors; Marijuana cessation; Reasons for using; Frequency of marijuana use; Social roles 50, 109

Prenatal exposure; Cocaine; Intelligence; Child development 50, 203

Prison; HIV transmission; Mathematical model; Injecting; Syringe sharing 50, 197

Psychopathology; Cocaine; Dependence; Treatment; Comorbidity 50, 9

Rats; Opioid withdrawal syndrome; Control of withdrawal effects; Tizanidine 50, 81

Reasons for using; Marijuana cessation; Predictors: Frequency of marijuana use; Social roles 50, 109

Reinforcement (psychology); Marijuana; Drug dependence; Conduct disorder 50, 27

RTI-15; Cocaine; Drug discrimination; Locomotor activity 50, 123

Scotland: Methadone treatment outcomes; Injecting; Crime; HIV risk behaviour 50, 47

Screening: Computers; Acceptability; Clinical; Drug and alcohol 50, 177

Selection bias; Acquired immunodeficiency syndrome: Injection drug users; Human immunodeficiency virus; Geographic information systems; Attrition; Neighborhood characteristics 50, 167

Self-control; Impulsivity; Substance dependence; Substance abuse; Adult 50, 137

Serotonin; β-Carbolines; Harmaline; Harmine; Drug discrimination; Hallucinogens; 5-HT, receptors 50, 99

Social roles; Marijuana cessation; Predictors; Reasons for using; Frequency of marijuana use 50, 109

Structural equation modeling: Alcohol; Dependence; Consequences; Bi-axial 50, 211

Subjective drug effects; Analgesia; Morphine; LY297802; Muscarinic agonist; Abuse liability; Humans 50, 129

Substance abuse: Impulsivity; Self-control; Substance dependence; Adult 50, 137

Substance abuse; Methadone maintenance; Opioids; Drug dosage; Gender 50, 233

Substance dependence; Impulsivity; Self-control; Substance abuse; Adult 50, 137

Substance use; Adolescence; Development; Latent growth modeling 50, 57

Syringe sharing; HIV transmission; Prison; Mathematical model; Injecting 50, 197

49-Tetrahydrocannabinol: Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTP/S binding; Autoradiography; Cannabinoids; Opiates; Morphine dependence 50, 241

Tizanidine; Opioid withdrawal syndrome; Rats; Control of withdrawal effects 50, 81

Treatment: Buprenorphine: Naloxone: Opioid-dependence 50, 1

Treatment; Cocaine; Dependence; Psychopathology; Comorbidity 50, 9

